General MedicationsINTRAVENOUSGeneric

VISTIDE

CIDOFOVIR

Standard Dose

EQ 375MG BASE/5ML (EQ 75MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview VISTIDE is listed in Drugs@FDA under application 020638 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CIDOFOVIR Form and strength SOLUTION;INTRAVENOUS - EQ 375MG BASE/5ML (EQ 75MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2013-11-13 00:00:00.

Structured Monograph

Clinical summary

Approval overview VISTIDE is listed in Drugs@FDA under application 020638 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CIDOFOVIR Form and strength SOLUTION;INTRAVENOUS - EQ 375MG BASE/5ML (EQ 75MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2013-11-13 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.